Murine interferon-α

• US 6,312,924 B1
• Filed: 03/17/2000
• Issued: 11/06/2001
• Est. Priority Date: 03/18/1999
• Status: Expired due to Fees

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Gao, Zeren, Presnell, Scott R., Feldhaus, Andrew L.
• Primary Examiner(s): Kemmerer, Elizabeth
• Assistant Examiner(s): Andres, Janet L.
• Application Number:
  US09/528,760
• Time in Patent Office: 599 Days
• Field of Search: 435/69.51, 435/320.1, 435/325, 435/70.5, 435/252.3, 435/254.11, 435/348, 435/349, 435/419, 530/351, 536/23.52, 536/23.1, 514/2
• US Class Current: 435/69.51
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/56 IFN-alpha
• CPC Class Codes: Y10S 977/918 Immunological
• CPC Class Codes: Y10S 977/927 Diagnostic contrast agent

Abstract

Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. The present invention provides a new form of murine interferon-α, which has applications in diagnosis and therapy.

Claims

1. An isolated nucleic acid molecule, wherein the nucleic acid molecule encodes the amino acid sequence of SEQ ID NO:

2.

2. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence of nucleotides 23 to 619 of SEQ ID NO:

1.

3. An isolated nucleic acid molecule that encodes a polypeptide having an amino acid sequence that is a variant of the amino acid sequence of SEQ ID NO:

2, wherein any difference between the amino acid sequence encoded by the nucleic acid molecule and the corresponding amino acid sequence of SEQ ID NO;

2 is due to a conservative amino acid substitution and wherein the encoded polypeptide exhibits anti-viral or anti-proliferative activity.

4. The isolated nucleic acid molecule of claim 3, wherein the amino acid sequence encoded by the nucleic acid molecule is characterized by at least one amino acid substitution within SEQ ID NO:

2 selected from the group consisting of;

(a) an alanine for glycine³⁹, (b) a valine for leucine⁶³, (c) a threonine for serine⁸¹, (d) a valine for isoleucine¹⁰⁵, and (e) a leucine for valine¹¹³.

5. The isolated nucleic acid molecule of claim 3, wherein the nucleic acid molecule encodes a polypeptide that exhibits anti-viral activity.

10. A vector, comprising the isolated nucleic acid molecule of claim 3.

6. An isolated nucleic acid molecule that encodes a polypeptide comprising amno acid residues 22 to 188 of SEQ ID NO:

2.

7. The isolated nucleic acid molecule of claim 6, comprising the nucleotide sequence of nucleotides 86 to 586 of SEQ ID NO:

1.

8. The isolated nucleic acid molecule of claim 6, wherein the polypeptide comprises amino acid residues 22 to 199 of SEQ ID NO:

2.

9. The isolated nucleic acid molecule of claim 8, comprising the nucleotide sequence of nucleotides 86 to 619 of SEQ ID NO:

1.

11. A vector, comprising the isolated nucleic acid molecule of claim 6.

12. A vector, comprising the isolated nucleic acid molecule of claim 8.

13. An expression vector, comprising the nucleic acid molecule of claim 8, a transcription promoter, and a transcription terminator, wherein the promoter is operably linked with the nucleic acid molecule, and wherein the nucleic acid molecule is operably linked with the transcription terminator.

14. A recombinant host cell comprising the expression vector of claim 13, wherein the host cell is selected from the group consisting of bacterium, yeast cell, fungal cell, insect cell, avian cell, mammalian cell, and plant cell.

15. The recombinant host cell of claim 14, wherein the host cell is a bacterium.

16. The recombinant host cell of claim 14, wherein the host cell is a yeast cell.

17. The recombinant host cell of claim 14, wherein the host cell is a fungal cell.

18. The recombinant host cell of claim 14, wherein the host cell is a insect cell.

19. The recombinant host cell of claim 14, wherein the host cell is a avian cell.

20. The recombinant host cell of claim 14, wherein the host cell is a mammalian cell.

21. The recombinant host cell of claim 14, wherein the host cell is a plant cell.

22. A method of producing a polypeptide that comprises amino acid residues 22 to 199 of SEQ ID NO:

2, the method comprising the step of culturing recombinant host cells that comprise the expression vector of claim 13, and that produce the polypeptide.

23. The method of claim 22, further comprising the step of isolating the polypeptide from the cultured recombinant host cells.